Trial Profile
Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE (1x10exp8 TCID50) Versus Liquid Formulation IMVAMUNE (1x108 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE (2x10exp7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naive Individuals.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Smallpox vaccine (Primary) ; Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics
- 19 Aug 2022 According to media release, European Medicines Agency s Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox, the ETF reviewed data from this clinical trial.
- 14 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.